Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Ariad Pharmaceuticals to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership.

Earnings & Valuation

This table compares Ariad Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ariad Pharmaceuticals N/A N/A -133.28
Ariad Pharmaceuticals Competitors $290.27 million $35.99 million 58.47

Ariad Pharmaceuticals’ peers have higher revenue and earnings than Ariad Pharmaceuticals. Ariad Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

87.0% of Ariad Pharmaceuticals shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 8.2% of Ariad Pharmaceuticals shares are held by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Ariad Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ariad Pharmaceuticals 0 4 1 0 2.20
Ariad Pharmaceuticals Competitors 913 3328 11821 237 2.70

Ariad Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential downside of 8.30%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.05%. Given Ariad Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe Ariad Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Ariad Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ariad Pharmaceuticals -60.47% N/A -17.16%
Ariad Pharmaceuticals Competitors -5,117.91% -159.14% -33.58%

Summary

Ariad Pharmaceuticals peers beat Ariad Pharmaceuticals on 7 of the 11 factors compared.

About Ariad Pharmaceuticals

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.